Novartis was the sole bidder in $12B deal to buy Aviditynews2025-11-25T09:00:28+00:00November 25th, 2025|Endpoints News|
FDA’s Pazdur is said to raise questions about commissioners actions, new vouchernews2025-11-24T21:04:48+00:00November 24th, 2025|Endpoints News|
UK-US drug pricing deal could come as early as this week, sources saynews2025-11-24T20:53:12+00:00November 24th, 2025|Endpoints News|
#ASH25: Kelonia’s first in vivo CAR-T data; Lilly, J&J and Novartis spell out Phase 3 winsnews2025-11-24T20:51:46+00:00November 24th, 2025|Endpoints News|
J&J’s tau-targeting antibody fails Phase 2 Alzheimer’s studynews2025-11-24T16:22:48+00:00November 24th, 2025|Endpoints News|
Kelun’s TROP2 ADC plus Keytruda improves outcomes in first-line lung cancernews2025-11-24T15:59:45+00:00November 24th, 2025|Endpoints News|
Sarepta to pay $200M milestone to Arrowhead; Enlivex reports osteoarthritis datanews2025-11-24T15:39:54+00:00November 24th, 2025|Endpoints News|
Biogen pens I&I deal with new Versant macrocycle developer Dayra Therapeuticsnews2025-11-24T12:30:38+00:00November 24th, 2025|Endpoints News|
Bayer’s stock rallies as next-gen blood thinner beats the odds with Phase 3 winnews2025-11-24T12:13:03+00:00November 24th, 2025|Endpoints News|
Novo Nordisk’s semaglutide misses in closely-watched Alzheimer’s trialsnews2025-11-24T12:10:32+00:00November 24th, 2025|Endpoints News|
